Lumida
/PCRX
⌘K
Pacira Biosciences Inc

Pacira Biosciences Inc

PCRX
$25.36USD+0.79%+0.20 today

MARKET CAP

1.0B

P/E (TTM)

211.3x

FWD P/E

DAY RANGE

$25 – $26

52W RANGE

$19
$28

AI Summary

Stalk
Buy NowMedium

PCRX remains in a Stage 2 advance with an active Momentum Breakout clearing the consolidation high, and EMAs aligned bullishly. Price is tracking above rising 9/20/50 EMAs with RSI supportive, validating near-term participation. Execution favors buying shallow pullbacks into the 20-day EMA near recent support. Primary risks include overhead resistance at the prior swing high and a decisive close below the 50-day SMA.

  • Q2 revenue reached $192.4 M (+6% YoY) with adjusted EBITDA of $48.7 M
  • Exparel now covers over 150 M lives, widening U.S. market access
  • Elective surgery volumes sensitive to macroeconomic swings, slowing growth
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$541.5M$666.8M$675.0M$701.0M$726.4M
YoY %+26.0%+23.1%+1.2%+3.9%+3.6%
P / Sales5.1x2.7x2.5x1.2x1.6x
EV / Sales6.5x3.9x3.3x2.0x2.2x
Gross Profit, Adj.$401.3M$467.5M$490.3M$530.5M$576.7M
YoY %+28.5%+16.5%+4.9%+8.2%+8.7%
Margin %74.1%70.1%72.6%75.7%79.4%
EV / Gross Profit8.7x5.6x4.5x2.6x2.7x
EBITDA, Adj.$118.5M$162.4M$163.2M$168.7M$110.2M
YoY %+61.0%+37.1%+0.5%+3.3%-34.7%
Margin %21.9%24.4%24.2%24.1%15.2%
EV / EBITDA29.6x16.1x13.6x8.1x14.3x
EBIT$89.9M$60.0M$87.7M$-73.4M$19.2M
YoY %+94.0%-33.3%+46.1%-183.7%+126.2%
Margin %16.6%9.0%13.0%-10.5%2.6%
EV / EBIT39.0x43.5x25.3x-18.7x82.3x
Net Income$42.0M$15.9M$42.0M$-99.6M$7.0M
YoY %-71.2%-62.1%+163.7%-337.3%+107.1%
Net Margin7.8%2.4%6.2%-14.2%1.0%
EPS (GAAP)$0.92$0.34$0.89-$2.15$0.16
YoY %-72.4%-63.0%+161.8%-341.6%+107.4%